Add to a list

Inactive Instrument

Oncorus, Inc. Stock

ONCR

US68236R1032

Biotechnology & Medical Research

OTC Markets Traded

Analysts' recommendations: Oncorus, Inc.

22-12-01	Chardan Downgrades Oncorus to Neutral From Buy After Announced Pipeline Reprioritization, Workforce Reduction; Withdraws Price Target	MT
22-06-15	Chardan Research Initiates Oncorus at Buy with $5 Price Target	MT
22-05-19	Piper Sandler Adjusts Oncorus' Price Target to $12 From $40, Reiterates Overweight Rating	MT
22-03-28	HC Wainwright Starts Oncorus at Buy With $7 Price Target	MT
22-03-10	Maxim Group Adjusts Oncorus Price Target to $7 From $20, Maintains Buy Rating	MT

More recommendations

Managers and Directors: Oncorus, Inc.

Manager	Title	Age	Since
Gina Balderas COO	Chief Operating Officer	-	-
Stephanie Duncanson PRN	Corporate Officer/Principal	-	-
Chris German AUD	Comptroller/Controller/Auditor	-	-

More insiders

Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company's two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
ONCR Stock

The best tools reserved for subscribers to boost the performance of your investments!

23-08-03	Oncorus, Inc. Announces Executive Changes	CI
23-08-03	Oncorus, Inc. Announces Changes to Its Board	CI
23-08-03	Oncorus, Inc. Announces Executive Changes	CI
23-07-28	Oncorus, Inc. Announces Board Changes	CI
23-07-19	Oncorus, Inc. Announces Resignation of Douglas M. Fambrough III from its Board of Directors as Well as Compensation Committee, Effective July 20, 2023	CI
23-07-19	Oncorus, Inc. Enters into Lease Termination Agreement with IQHQ-4 Corporate, LLC	CI
23-06-23	Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index	CI
23-06-20	Oncorus, Inc.(OTCPK:ONCR) dropped from NASDAQ Composite Index	CI
23-06-07	Oncorus Announces Management Changes	CI
23-06-07	Oncorus Appoints Brian Shea as Interim Chief Executive Officer	CI
23-06-02	Debt Limit Deal Approval, Jobs Data in Focus Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Friday	MT
23-06-01	Oncorus to Lay Off Almost Entire Workforce -- Shares Slump After-Hours	MT
23-06-01	Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus	DJ

23-07-19	Oncorus : Termination of Material Agreement - Form 8-K	PU
23-07-06	Nanocap Potential Breakout Watchlist (EPAZ, GCAN, IQST, ONCR)	AQ
23-06-01	ONCORUS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23-06-01	Oncorus Announces Workforce Reduction Plan	AQ
23-06-01	Oncorus Announces Workforce Reduction Plan	GL

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/6/23	Brian Shea	Other	Chief Executive Officer	61,085	0.2341%
12/28/22	Deerfield Management Co. LP	Sell	Company	336,235	1.2945%
12/22/22	Deerfield Management Co. LP	Sell	Company	73,384	0.2825%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCORUS, INC.	-3.08%	+869.23%	-	-	3.29M
WUXI APPTEC CO., LTD.	+0.21%	-4.63%	+55.34%	+71.32%	68.92B
ARGENX SE	+1.66%	+7.51%	+8.12%	+60.04%	51.9B
LONZA GROUP AG	+3.14%	+7.17%	+12.48%	+44.42%	48.73B
IQVIA HOLDINGS INC.	+3.45%	+4.70%	+33.44%	+35.96%	43.13B
REVOLUTION MEDICINES, INC.	-2.20%	+0.61%	+281.88%	+532.76%	41.48B
BEONE MEDICINES AG	+6.43%	+6.84%	+18.32%	+109.23%	39.96B
CELLTRION, INC.	+1.28%	+1.39%	+11.69%	+45.10%	30.6B
WUXI BIOLOGICS (CAYMAN) INC.	+2.63%	-7.48%	+35.90%	+1.67%	26.01B
BIONTECH SE	+1.74%	-2.02%	-13.55%	-12.92%	22.27B
Average	+1.51%	-0.94%	+49.29%	+98.62%	41.44B
Weighted average by Cap.	+1.90%	-0.25%	+52.81%	+105.49%

Oncorus, Inc. Stock

Stocks

ONCR

US68236R1032

Biotechnology & Medical Research

Latest news: Oncorus, Inc.

Analysts' recommendations: Oncorus, Inc.

Press Releases: Oncorus, Inc.

Quotes and Performance

Managers and Directors: Oncorus, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile